Cyclodextrin Complexes: Utility in Improving Drug Bioavailability and Other Applications
Bioequivalence & Bioavailability International Journal · 2018
DOI: 10.23880/beba-16000130 ↗Kurz gefasst
Fachartikel in der Zeitschrift Bioequivalence & Bioavailability International Journal, 2018. Verfasst von Onyeji CO.
Abstract (Originalsprache)
The oral route is the most common and preferred method of drug administration because of its convenience and ease of delivery as well as cost-effectiveness and better patient compliance. However, for many active pharmaceutical ingredients (APIs), this route of administration is associated with some drawbacks such as poor aqueous solubility and low permeability of the compound resulting in limited drug absorption and consequent poor bioavailability. For any drug to be absorbed, it must be available in an aqueous solution at the site of absorption. It is known that for drugs with solubilities < 0.1 mg/ml, their absorption are likely to be dissolution limited. Conversely, if a drug is extremely water soluble, its ability to traverse lipophilic biomembranes (permeability) will be poor and this also limits the bioavailability. The critical impacts of aqueous solubility and intestinal permeability of drugs on their bioavailability have been utilized in classifying APIs into four classes, as reflected in the Biopharmaceutics Classification Systems (BCS). These two factors along with dissolution process, govern the rate and extent to which a drug appears in the systemic circulation, and this depicts bioavailability. For the BCS class II drugs (low aqueous solubility/high permeability) the rate-limiting step in drug absorption is the dissolution process. While for the BCS Class IV drugs (low aqueous solubility/low permeability), both dissolution process and intestinal permeability determine the drug absorption. Thus, increasing the aqueous solubility can translate to increase in the dissolution rate with a resultant improvement in the oral bioavailability of BCS Classes II and IV drugs. The BCS classes 1 and III drugs are not subject to bioavailability problems since they both have high aqueous solubility but with high and low permeability, respectively.
Zitieren
APA
CO, O. (2018). Cyclodextrin Complexes: Utility in Improving Drug Bioavailability and Other Applications. Bioequivalence & Bioavailability International Journal. https://doi.org/10.23880/beba-16000130
Vancouver
CO O. Cyclodextrin Complexes: Utility in Improving Drug Bioavailability and Other Applications. Bioequivalence & Bioavailability International Journal. 2018. doi:10.23880/beba-16000130
BibTeX
@article{CO2018,
author = {CO, Onyeji},
title = {Cyclodextrin Complexes: Utility in Improving Drug Bioavailability and Other Applications},
journal = {Bioequivalence & Bioavailability International Journal},
year = {2018},
doi = {10.23880/beba-16000130}
}
EUVIMED